The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
AREXVY GlaxoSmithKline Australia Pty Ltd
Product name
AREXVY
Accepted date
Apr-2024
Active ingredients
recombinant respiratory syncytial virus pre-fusion F protein
Proposed indication
For the prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV).
Application type
C (new indication)
Publication date
Apr-2024